Pierre Fabre engagements | NERLYNX
Partners of the Pierre Fabre Group: from health to beauty
Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Puma regains China rights to Nerlynx and amends deal with Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology | Evaluate
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Fight against cancer : our therapeutic responses | Pierre Fabre
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma regains China rights to Nerlynx and amends deal with Fabre
Blue March: Pierre Fabre supports colorectal cancer awareness month
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Accord entre Pierre Fabre et Puma Biotechnology
Partners of the Pierre Fabre Group: from health to beauty
THE FACES OF BREAST CANCER
